Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 8/20 | 0.55 |
| ▸ | BCHE | P06276 | 6/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269933 | 0.89 | SLC6A9 (0.71) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL10109825 | 0.89 | ACHE (0.59) | SLC6A9ACHEBCHEFAAHMARK4 | |
| SCHEMBL7943023 | 0.84 | SLC6A9 (0.72) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL12208533 | 0.82 | ACHE (0.58) | SLC6A9SLC6A4HRH3ACHEBCHE | |
| Toluene SCHEMBL8723129 | 0.82 | SLC6A9 (0.56) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL13780465 | 0.81 | SLC6A9 (0.77) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL8722264 | 0.80 | SLC6A9 (0.61) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL7939788 | 0.80 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL8722262 | 0.79 | SLC6A9 (0.67) | SLC6A9SLC6A4HRH3ACHENPC1 | |
| SCHEMBL13050309 | 0.78 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3ACHENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | COLUCID PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | COLUCID PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| WO-2010009316-A1 | STIGMINE CONJUGATES FOR SUBSTANCE USE DISORDERS | COLUCID PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090048229-A1 | Methods for promoting wakefulness | COLUCID PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048229-A1 | Methods for promoting wakefulness | COLUCID PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | TACR2, NPSR1, TACR3 | SLC6A9 869/4885SLC6A4 57/4885HRH3 425/4885 |
| US-20090048229-A1 | Methods for promoting wakefulness | HCRTR2, HCRTR1, CHAT | SLC6A9 1085/4885SLC6A4 157/4885HRH3 54/4885 |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | SLC6A9 2535/4885SLC6A4 1102/4885HRH3 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.